Meeting
2020 Gastrointestinal Cancers Symposium
The impact of pancreatic cancer resection in the era of effective systemic treatment.
Authors
Yaacov Richard Lawrence
Sheba Medical Center, Ramat Gan, Israel
Yaacov Richard Lawrence , Ofer Margalit , Galia Jacobson , Liat Hamer , Uri Amit , Naama Halpern , Einat Shacham Shmueli , Ben Boursi , Yuri Goldes , Daniel Azoulay , Talia Golan , Zvi Symon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 722)
Abstract #
722
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2019 Gastrointestinal Cancers Symposium
Pathologic outcomes of systemic therapy followed by stereotactic body radiation therapy (SBRT) for pancreatic cancer (PC) in a novel lateral decubitus treatment position.
First Author: Ethan Song
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2018 Gastrointestinal Cancers Symposium
Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.
First Author: Sunnie S. Kim